Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents

Clin Obstet Gynecol. 2023 Mar 1;66(1):196-207. doi: 10.1097/GRF.0000000000000740. Epub 2022 Aug 10.

Abstract

Increasing rates of thromboembolic complications have required increasing use of anticoagulant and antiplatelet agents during and after pregnancy. Furthermore, thromboembolism is both a cause and a complication of severe maternal morbidity requiring intensive care. As a consequence, almost all patients admitted to intensive care units receive an anticoagulant or an antiplatelet agent (or both) for either treatment or prevention of thromboembolism. In this review, we summarize commonly used anticoagulants and antiplatelet agents and outline the potential role of newly developed (novel) antithrombotic agents for pregnant and postpartum patients.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anticoagulants / therapeutic use
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Pregnancy
  • Thromboembolism* / drug therapy
  • Thromboembolism* / prevention & control

Substances

  • Platelet Aggregation Inhibitors
  • Anticoagulants
  • Fibrinolytic Agents